Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Safety characterized by type, incidence, severity, timing, seriousness and relationship to study treatment of adverse events and laboratory abnormalities.

Defined as the time from date of the first documentation of objective tumor response (CR or PR) to the first documentation of either Progression of Disease (PD) or death due to any cause, whichever occurs first.

Defined as time from first study treatment until disease progression or death from any cause, whichever occurs first.

1-Year Survival rate

Overall Survival (OS)

Pharmacokinetics (PK) Blood plasma Adagrasib and potential metabolite concentrations

Safety characterized by type, incidence, severity, timing, seriousness and relationship to study treatment of adverse events and laboratory abnormalities.

Pharmacokinetics (PK) Blood plasma Adagrasib and potential metabolite concentrations

Patient Reported Outcomes to measure quality of life

Defined as time from first study treatment until disease progression or death from any cause, whichever occurs first.

Defined as the time from date of the first documentation of objective tumor response (CR or PR) to the first documentation of either Progression of Disease (PD) or death due to any cause, whichever occurs first.

Defined as the percent of patients documented to have a confirmed CR or PR.